scholarly journals Expression of Human Serum Albumin in Milk of Transgenic Mice Using Goat β-casein/Human Serum Albumin Fusion Gene

2004 ◽  
Vol 17 (6) ◽  
pp. 743-749
Author(s):  
H. T. Wu ◽  
C. K. Chou ◽  
M. C. Huang
1993 ◽  
Vol 2 (5) ◽  
pp. 266-276 ◽  
Author(s):  
Itamar Barash ◽  
Alexander Faerman ◽  
Ariela Baruch ◽  
Margaret Nathan ◽  
David R. Hurwitz ◽  
...  

1992 ◽  
Vol 1 (5) ◽  
pp. 195-208 ◽  
Author(s):  
Moshe Shani ◽  
Itamar Barash ◽  
Margret Nathan ◽  
George Ricca ◽  
George H. Searfoss ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Shuqiang Zhao ◽  
Yu Zhang ◽  
Hong Tian ◽  
Xiaofei Chen ◽  
Di Cai ◽  
...  

Protein fusion technology is one of the most commonly used methods to extend the half-life of therapeutic proteins. In this study, in order to prolong the half-life of Granulocyte colony stimulating factor (G-CSF), the domain III of human serum albumin (3DHSA) was genetically fused to the N-terminal of G-CSF. The 3DHSA-G-CSF fusion gene was cloned intopPICZαA along with the open reading frame of theα-factor signal under the control of the AOX1 promoter. The recombinant expression vector was transformed intoPichia pastoris GS115, and the recombinant strains were screened by SDS-PAGE. As expected, the 3DHSA-G-CSF showed high binding affinity with HSA antibody and G-CSF antibody, and the natural N-terminal of 3DHSA was detected by N-terminal sequencing. The bioactivity and pharmacokinetic studies of 3DHSA-G-CSF were respectively determined using neutropenia model mice and human G-CSF ELISA kit. The results demonstrated that 3DHSA-G-CSF has the ability to increase the peripheral white blood cell (WBC) counts of neutropenia model mice, and the half-life of 3DHSA-G-CSF is longer than that of native G-CSF. In conclusion, 3DHSA can be used to extend the half-life of G-CSF.


1994 ◽  
Vol 3 (3) ◽  
pp. 141-151 ◽  
Author(s):  
Itamar Barash ◽  
Alexander Faerman ◽  
Tamar Ratovitsky ◽  
Raisa Puzis ◽  
Margaret Nathan ◽  
...  

2021 ◽  
Vol 03 (01) ◽  
pp. e30-e37
Author(s):  
Gui-Hua Gong ◽  
Shu Han ◽  
Xiao-Ling Huang ◽  
Li-Ping Xie ◽  
Wei Zhang ◽  
...  

AbstractHuman serum albumin (HSA) is widely used in the clinic for the treatment of several diseases in large amount each year. With the increasing demands of HSA in clinic and limited blood resource, recombinant HSA (rHSA) is becoming an attractive and alternative source for HSA production. In this study, we aimed to express rHSA in the mammary glands of transgenic mice by using a tissue-specific promoter and other regulatory elements. An rHSA expression vector was constructed bearing the cDNA and first intron of HSA under the control of bovine αs1-casein promoter with a 2 × chicken β-globin insulator in the front. Transgenic mice were generated and reverse transcription polymerase chain reaction showed that rHSA was expressed only in the mammary gland, indicating the tissue specificity of the bovine αs1-casein promoter in directing transgene transcription in transgenic mice. Enzyme-linked immunosorbent assay test showed that rHSA was successfully secreted into the milk of transgenic mice with the highest level at 1.98 ± 0.12 g/L. Our results indicate the ability of the bovine αs1-casein promoter to induce successful expression of rHSA in the mammary gland of transgenic mice.


Sign in / Sign up

Export Citation Format

Share Document